Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients

Title
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients
Authors
Keywords
Neutrophil/lymphocyte ratio, Metastatic colorectal cancer, Bevacizumab, Systemic inflammation
Journal
MEDICAL ONCOLOGY
Volume 31, Issue 9, Pages -
Publisher
Springer Nature
Online
2014-08-22
DOI
10.1007/s12032-014-0166-6

Ask authors/readers for more resources

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started